Timothy P. Hughes - Articles and news items

Novartis logo
Novartis logo

Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Glivec® in slowing disease progression in patients

Industry news, News / 6 December 2010 / Novartis

with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+